01—Abstract
Summary
Summary of the 8-K filed February 5, 2025. Cited figures are marked; the original filing is the authoritative source.
McKesson (MCK) reported preliminary fiscal Q3 2025 results for the quarter ended December 31, 2024, with consolidated revenues of $95.3 billiona, up 18% year over year, driven mainly by U.S. Pharmaceutical volume growth and the oncology platform.
GAAP diluted EPS was $6.95b, up sharply from $4.42, but that comparison is flattered by the prior-year Rite Aid bad-debt charge. Adjusted diluted EPS was $8.03, up 4%, helped by a lower share count and operational growth but offset by a higher tax rate. GAAP net income attributable to McKesson fell 8% year to date to $2.0 billion, and the nine-month GAAP operating profit rose 10%.
Management raised and narrowed fiscal 2025 Adjusted EPS guidance to $32.55c-$32.95 from $32.40-$33.00, implying 19-20% growth. The guidance includes $0.57 of year-to-date gains from McKesson Ventures' equity investments, so the underlying raise is smaller than the headline suggests. Cash generation was weak: nine-month operating cash flow was negative $1.7 billion and free cash flow was negative $2.2 billion, driven by working capital build in receivables and inventories.
Balance sheet data shows cash falling to $1.1 billiond, short-term borrowings of $2.4 billion, and a stockholders' deficit, while the company returned $3.1 billion to shareholders year to date through $2.8 billion in buybacks and $254 million in dividends. Strategic activity included a definitive agreement to acquire an 80% controlling interest in PRISM Vision Holdings, a retina and ophthalmology management platform, and the December 30, 2024 closing of the sale of the Canadian Rexall and Well.ca retail businesses.
The filing is a furnished (not filed) 8-K under Item 2.02, and the figures are unaudited and preliminary. Investors should weigh the strong top-line and adjusted earnings growth against negative free cash flow, reliance on non-GAAP adjustments, and the one-time items that shape the reported GAAP comparisons.
02—Key points
Key Highlights
- Revenue of $95.3B rose 18% YoY, led by U.S. Pharmaceutical (up 19% to $87.1B) on higher prescription volumes and oncology growth.
- GAAP diluted EPS of $6.95 was up 57% from $4.42, but the prior-year quarter included a Rite Aid bankruptcy bad-debt charge, so the increase is largely a easy comparison.
- Adjusted diluted EPS of $8.03 rose 4%; adjusted operating profit grew 16% to $1.46B, while adjusted net earnings fell 2% because of a higher tax rate.
- FY2025 Adjusted EPS guidance narrowed to $32.55-$32.95 (from $32.40-$33.00), still implying 19-20% growth, but it includes $0.57 of year-to-date McKesson Ventures investment gains.
- Nine-month free cash flow was negative $2.2B (operating cash flow of -$1.7B), with receivables and inventory build absorbing cash; cash fell to $1.1B and short-term borrowings rose to $2.4B.
- Capital returns continued at $3.1B year to date ($2.8B buybacks, $254M dividends), while the company carries a total stockholders' deficit of $2.7B.
- Announced agreement to acquire an 80% controlling interest in PRISM Vision Holdings (retina/ophthalmology services), subject to regulatory clearance; the Canadian Rexall and Well.ca retail sale closed December 30, 2024.
03—Questions
Frequently Asked Questions
Why did GAAP EPS rise so much while adjusted EPS grew only 4%?
The prior-year quarter included a large provision for bad debts tied to the Rite Aid bankruptcy, which depressed GAAP EPS to $4.42. Lapping that charge drives most of the $2.53 GAAP increase. Adjusted EPS excludes such items and grew 4% to $8.03, helped by operational growth and a lower share count but held back by a higher tax rate.
Is the FY2025 guidance raise meaningful?
Only modestly. The range was narrowed to $32.55-$32.95 from $32.40-$33.00, so the midpoint moved only slightly, from $32.70 to $32.75. Management attributes $0.57 of the guidance to year-to-date gains on McKesson Ventures' equity investments, which are not recurring operating earnings.
Why is free cash flow negative despite strong earnings?
Nine-month operating cash flow was negative $1.7B, as growth in receivables ($4.1B) and inventories ($3.1B) outpaced payables gains. Capital expenditures and capitalized software added another $581M of outflow, producing free cash flow of negative $2.2B. Investors should watch whether working capital normalizes in the fourth quarter.
What does the PRISM Vision acquisition mean for McKesson?
McKesson agreed to acquire an 80% controlling interest in PRISM Vision Holdings, a provider of general ophthalmology and retina management services. It extends McKesson's practice-management model from oncology into the high-growth retina segment. The deal requires customary closing conditions and regulatory clearance, and the filing does not disclose its purchase price or financial impact.
Are these results audited or final?
No. The filing states the results are preliminary and unaudited, and the document is furnished under Item 2.02 rather than filed, so it is not subject to Section 18 liability unless specifically incorporated. Investors should rely on the company's Form 10-Q for the audited-review quarter and note that non-GAAP measures lack standardized definitions across peers.
04—Continue